Related Experiment Video

Updated: Jul 31, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

FTY720 inhibits tumor growth and angiogenesis

G Schmid1, M Guba, A Papyan

  • 1Department of Surgery, University of Munich, Klinikum Grosshadern, Munich, Germany.

Transplantation Proceedings
|April 6, 2005
PubMed

Insights

FTY720, an immunosuppressant, demonstrated significant antiangiogenic and antitumor effects in vitro and in vivo. This drug may offer a promising therapeutic strategy for allograft recipients prone to tumor development.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • De novo malignancies and tumor recurrence pose significant risks for allograft recipients undergoing chronic immunosuppression.
  • FTY720, a synthetic myriocin analogue, is an immunosuppressant known to prolong allograft survival by inducing lymphocyte apoptosis and preventing infiltration.
  • Previous studies indicated FTY720's potential in preventing tumor growth and metastasis.

Purpose of the Study:

  • To investigate the antiangiogenic effects of FTY720 using a human umbilical vein endothelial cell (HUVEC) spheroid model.
  • To evaluate the in vivo antitumor efficacy of FTY720 in a murine Lewis Lung Carcinoma (LLC1) model.

Main Methods:

  • In vitro: Assessed FTY720's effect on angiogenesis in HUVEC spheroids, including its interaction with vascular endothelial growth factor (VEGF).
  • In vivo: Administered daily doses of FTY720 (1, 5, or 10 mg/kg) or saline to C57/B16 mice bearing subcutaneous LLC1 tumors.
  • Monitored tumor size periodically after palpable tumor establishment.

Main Results:

  • FTY720 exhibited a potent antiangiogenic effect in vitro, counteracting VEGF-induced stimulation even at subnanomolar concentrations.
  • In vivo, FTY720 demonstrated dose-dependent inhibition of subcutaneous tumor growth.
  • Tumor size in mice treated with 10 mg/kg FTY720 was reduced by more than 50% compared to control animals.

Conclusions:

  • FTY720 possesses significant antiangiogenic and antitumor properties.
  • The pericyte-stabilizing effect may limit FTY720's efficacy in this specific mouse model.
  • Combining FTY720 with an mTOR inhibitor could be an optimal immunosuppressive strategy for at-risk allograft recipients.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...